0 期临床试验：加速化学预防药物的开发。
Phase 0 trials: expediting the development of chemoprevention agents.
机构信息
Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
出版信息
Cancer Prev Res (Phila). 2011 Mar;4(3):288-92. doi: 10.1158/1940-6207.CAPR-11-0013.
Abstract
Phase 0 trials are first-in-human clinical trials performed under the Exploratory IND [investigational new drug] Guidance of the U.S. Food and Drug Administration. Unlike traditional phase I trials, these studies have no therapeutic or diagnostic intent but instead aim to provide only pharmacokinetic and/or pharmacodynamic data to inform the next step in developing an agent. We discuss the role that such trials, including one reported by Reid and colleagues (beginning on page 347 in this issue of the journal), can play in expanding the number of drugs that are evaluated for chemoprevention while compressing the drug-development timeline.
摘要
阶段 0 试验是根据美国食品和药物管理局的探索性 IND（研究性新药）指导原则进行的首次人体临床试验。与传统的 I 期试验不同，这些研究没有治疗或诊断目的，而是旨在仅提供药代动力学和/或药效学数据，为开发药物的下一步提供信息。我们讨论了此类试验（包括 Reid 及其同事报告的一项试验，该试验见本期杂志第 347 页）在扩大用于化学预防的药物数量的同时压缩药物开发时间线上可以发挥的作用。
相似文献
1
Phase 0 trials: expediting the development of chemoprevention agents.0 期临床试验：加速化学预防药物的开发。
Cancer Prev Res (Phila). 2011 Mar;4(3):288-92. doi: 10.1158/1940-6207.CAPR-11-0013.
2
The next phase of chemoprevention research.化学预防研究的下一阶段。
Cancer Prev Res (Phila). 2011 Mar;4(3):293-5. doi: 10.1158/1940-6207.CAPR-11-0012.
3
Curcumin chemoprevention: the long road to clinical translation.姜黄素化学预防：通往临床转化的漫漫长路。
Cancer Prev Res (Phila). 2011 Mar;4(3):296-8. doi: 10.1158/1940-6207.CAPR-11-0060.
4
Food extracts for chemoprevention: quo vadis?用于化学预防的食物提取物：路在何方？
Cancer Prev Res (Phila). 2009 Jul;2(7):608-10. doi: 10.1158/1940-6207.CAPR-09-0102.
5
Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.Akt 抑制剂 SR13668 的 0 期临床化学预防试验。
Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. doi: 10.1158/1940-6207.CAPR-10-0313.
6
Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.用于大规模化学预防试验的队列选择的癌症风险因素。
J Cell Biochem Suppl. 1996;25:29-36.
7
Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.癌症化学预防的进展：药物选择及短期临床干预试验的观点
Cancer Res. 1994 Apr 1;54(7 Suppl):2015s-2024s.
8
Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.美国国立癌症研究所研讨会执行摘要：要点与建议
Urology. 2001 Apr;57(4 Suppl 1):4-27. doi: 10.1016/s0090-4295(00)00931-6.
9
Chemoprevention clinical trials.化学预防临床试验。
Mutat Res. 1992 Jun;267(2):291-5. doi: 10.1016/0027-5107(92)90073-b.
10
How should we move the field of chemopreventive agent development forward in a productive manner?我们应该如何以富有成效的方式推动化学预防剂开发领域向前发展？
Recent Results Cancer Res. 2005;166:113-24. doi: 10.1007/3-540-26980-0_9.
引用本文的文献
1
Phase 0 Clinical Trial Strategies for the Neurosurgical Oncologist.神经外科肿瘤学家的 0 期临床试验策略。
Neurosurgery. 2019 Dec 1;85(6):E967-E974. doi: 10.1093/neuros/nyz218.
2
Sophora flavescens Containing-QYJD Formula Activates Nrf2 Anti-Oxidant Response, Blocks Cellular Transformation and Protects Against DSS-Induced Colitis in Mouse Model.含苦参的清肠解毒方激活Nrf2抗氧化反应，阻断细胞转化并在小鼠模型中预防葡聚糖硫酸钠诱导的结肠炎。
Am J Chin Med. 2018 Oct 4:1-15. doi: 10.1142/S0192415X18500829.
3
New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers.癌症预防疗法临床转化中的新概念与挑战：药效学生物标志物的作用
Ecancermedicalscience. 2015 Nov 24;9:601. doi: 10.3332/ecancer.2015.601. eCollection 2015.
4
Nrf2-dependent suppression of azoxymethane/dextran sulfate sodium-induced colon carcinogenesis by the cinnamon-derived dietary factor cinnamaldehyde.肉桂来源的膳食因子肉桂醛通过Nrf2依赖性抑制偶氮甲烷/葡聚糖硫酸钠诱导的结肠癌发生。
Cancer Prev Res (Phila). 2015 May;8(5):444-54. doi: 10.1158/1940-6207.CAPR-14-0359. Epub 2015 Feb 23.
5
Cancer chemoprevention: a rapidly evolving field.癌症化学预防：一个快速发展的领域。
Br J Cancer. 2013 Jul 9;109(1):1-7. doi: 10.1038/bjc.2013.280. Epub 2013 Jun 4.
6
Early-phase development of cancer prevention agents: challenges and opportunities.癌症预防药物的早期开发：挑战与机遇。
Cancer Prev Res (Phila). 2013 May;6(5):379-83. doi: 10.1158/1940-6207.CAPR-12-0463. Epub 2013 Mar 6.
本文引用的文献
1
Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.Akt 抑制剂 SR13668 的 0 期临床化学预防试验。
Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. doi: 10.1158/1940-6207.CAPR-10-0313.
2
Microdosing: current and the future.微剂量给药：现状与未来。
Bioanalysis. 2010 Mar;2(3):509-17. doi: 10.4155/bio.09.177.
3
The statistics of phase 0 trials.零期临床试验的统计数据。
Stat Med. 2010 May 10;29(10):1072-6. doi: 10.1002/sim.3840.
4
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.国家外科辅助乳腺和肠道项目（National Surgical Adjuvant Breast and Bowel Project）他莫昔芬和雷洛昔芬（Tamoxifen and Raloxifene）试验（STAR）P-2 研究更新：预防乳腺癌。
Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.
5
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.0期临床试验的临床前模型：小鼠异种移植瘤活检中聚（ADP-核糖）聚合酶药效学检测的验证
Clin Cancer Res. 2008 Nov 1;14(21):6877-85. doi: 10.1158/1078-0432.CCR-08-0214.
6
Designing phase 0 cancer clinical trials.设计0期癌症临床试验。
Clin Cancer Res. 2008 Jun 15;14(12):3675-82. doi: 10.1158/1078-0432.CCR-07-4560.
7
Compressing drug development timelines in oncology using phase '0' trials.利用“0期”试验缩短肿瘤学药物研发周期。
Nat Rev Cancer. 2007 Feb;7(2):131-9. doi: 10.1038/nrc2066.
8
Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?提高药物研发效率的首次人体研究的非传统方法：微剂量研究是否会产生重大影响？
Clin Pharmacol Ther. 2007 Jan;81(1):24-6. doi: 10.1038/sj.clpt.6100058.
9
Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.使用微剂量法预测治疗剂量下的药代动力学：5种药物的经验
Clin Pharmacol Ther. 2006 Sep;80(3):203-15. doi: 10.1016/j.clpt.2006.05.008.
10
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.化学预防药物研发进展：分子生物标志物在预防上皮内瘤变和癌症方面的前景——前进计划
Clin Cancer Res. 2006 Jun 15;12(12):3661-97. doi: 10.1158/1078-0432.CCR-06-1104.
Zotero 插件